PROCEPT BioRobotics (PRCT) is back in focus after first quarter earnings showed sales of US$83.13 million and a wider net loss, alongside reaffirmed full year 2026 revenue and loss guidance.

The stock is trading at US$25.44, with recent momentum reflected in a 1 month share price return of 9.7% and a 7 day share price return of 5.8%. However, the year to date share price return of 17.3% and 1 year total shareholder return of 53.6% indicate that longer term holders have experienced meaningful declines despite the latest reaction to earnings and reaffirmed guidance.

If this earnings driven move has you thinking about other robotics opportunities, it is a good time to scan the market using our 32 robotics and automation stocks

With PROCEPT BioRobotics still loss making but guiding for higher 2026 sales, the key question is whether the recent rally leaves limited upside or if the current price reflects a potential entry before markets price in more growth.

Most Popular Narrative: 16.4% Undervalued

At a last close of $25.44 versus a narrative fair value of $30.44, the current set up hinges on how credible the BPH adoption story looks over time.

The ongoing expansion of HYDROS robotic system placements into both high volume and mid/lower volume hospitals, in conjunction with rising utilization by a growing base of engaged surgeons, indicates significant untapped market potential driving recurring consumables revenue growth and eventual expansion in gross and operating margins.

Want to see what underpins that confidence in recurring revenue and margin lift? The narrative leans on brisk top line growth, sharper margins and a rich future earnings multiple.

Result: Fair Value of $30.44 (UNDERVALUED)

However, that story can crack if Aquablation adoption stalls, or if ongoing operating losses and supplier or reimbursement setbacks drag longer than analysts currently expect.

Another View: Market Pricing Looks Full

That 16.4% narrative upside sits against a much tougher read from simple pricing metrics. PROCEPT BioRobotics trades on a P/S of 4.5x, compared with 2.8x for the US Medical Equipment industry and a fair ratio of 3.2x. This points to valuation risk if sentiment cools.

Next Steps

If this mix of optimism and concern has you uncertain, review the data promptly and form your own view using our 1 key reward and 2 important warning signs

Looking for more investment ideas?

If PROCEPT BioRobotics has sharpened your focus, now is the moment to widen your watchlist with other stocks that fit clear, data driven criteria.

• Target potential value opportunities by scanning companies highlighted in our 51 high quality undervalued stocks.
• Strengthen your focus on balance sheet resilience by checking stocks in the solid balance sheet and fundamentals stocks screener (44 results).
• Spot under the radar prospects with solid fundamentals using the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.